SOUTH SAN FRANCISCO, Calif., Nov. 1, 2017 /PRNewswire/ -- Perlara, a drug discovery platform company partnering with highly motivated families and drug developers to cure diseases thought too rare to matter, today announced the closing of a $7.4M round of equity financing with participation by Pivotal Capital Alpha, Al-Hamra Group, Radical Investments, Homebrew Ventures, Haystack Fund and existing investors, including Y Combinator. Novartis participated in the financing under the terms of its research collaboration with Perlara.
The company has raised a total of $9.9M since inception in 2014.
"With this funding we will be able to advance programs forward, discover novel lead compounds for our first three PerlQuest partners, and double our disease pipeline with the launch of six new PerlQuests," says Perlara founder and CEO Ethan Perlstein, PhD.
Perlara is a public benefit corporation working to develop cures for rare diseases and learn how genes work across diseases to map connections to common ailments. For general information and updates, please visit us at perlara.com, connect with us at @PerlaraPBC on Twitter and at www.facebook.com/PerlaraPBC on Facebook, and learn specifically about PerlQuests at www.perlara.com/perlquests and www.perlara.com/faqs.